These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 15298013

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A new history and discussion of 180-day exclusivity.
    Korn DE, Lietzan E, Scott SW.
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 9. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ.
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract] [Full Text] [Related]

  • 10. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR.
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D.
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The right to a jury trial under the Waxman-Hatch Act--the question revisited and resolved.
    Coggio BD, DeMasi TE.
    Food Drug Law J; 2002; 57(1):155-60. PubMed ID: 12118478
    [No Abstract] [Full Text] [Related]

  • 19. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS.
    Fed Regist; 2004 Feb 23; 69(35):8105-7. PubMed ID: 14997866
    [Abstract] [Full Text] [Related]

  • 20. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
    Fed Regist; 1998 Mar 06; 63(44):11174-7. PubMed ID: 10177511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.